Rajesh Kharbanda
Latest contributions
TAVI complications - Prediction, reduction, avoidance
21 May 2026 – From EuroPCR 2026
This session examines prediction, reduction, and avoidance of complications associated with TAVI procedures. It covers outcomes of second-valve implantation as a bail-out for valve migration, predictors of permanent pacemaker implantation post-TAVI from the LANDMARK trial, neurological event prognostics based on timing, and management of periprocedural cardiac...
Redo TAVI challenges
20 May 2026 – From EuroPCR 2026
Focused on the complexities of redo transcatheter aortic valve implantation (TAVI), this session covers innovative techniques such as jailed-balloon to prevent sinus sequestration, CT-guided emergency valve-in-valve procedures, alternative access routes, and strategies to manage coronary occlusion risks during multiple valve interventions.
Clinical implications of TAVI and cerebral embolic protection - Current challenges and future considerations
21 May 2025 – From EuroPCR 2025
Cerebral embolic protection (CEP) remains a key consideration in modern TAVI procedures, as stroke continues to be one of the most serious complications. This EuroPCR 2025 session takes a close look at the latest data on CEP use in clinical practice, weighing where it fits best...
TAVI: contemporary practice
21 May 2025 – From EuroPCR 2025
Stay updated on contemporary TAVI practices with insights from the 2024 European TAVI PATHWAY Registry. This session addresses comprehensive risk stratification in moderate aortic stenosis, safety and efficacy of repeat TAVI procedures, comparative outcomes of explant versus redo-TAVI after valve failure, and long-term neurological outcomes following...
Major Late-Breaking Trials from EuroPCR 2025
21 May 2025 – From EuroPCR 2025
Discover major late-breaking trials from EuroPCR 2025 in this session presenting pivotal study data. Highlights include meta-analyses from the PROTECTED TAVR and BHF PROTECT-TAVI studies, angiography versus physiology-guided PCI during TAVI (FAITAVI trial), and novel antiplatelet strategies following drug-coated stent implantation in acute coronary syndrome, with...
